ArticleInternational journal of chronic obstructive pulmonary disease2025
Multi-Criteria Decision Analysis of Biologics in Chronic Obstructive Pulmonary Disease.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Airway Diseases and Occupational Exposures in Poultry Industry Workers: A Comprehensive Review.Current allergy and asthma reports · 2026Review
- Biologics in Older Adults with Chronic Obstructive Pulmonary Disease: A Narrative Review.Journal of clinical medicine · 2026Review
- Review
- Review
- Review
- Unknotting the crosstalk between COPD and neuroinflammation.Journal of neuroinflammation · 2026Review
- The role of programmed cell death in chronic obstructive pulmonary disease: from pathogenesis to treatment.Frontiers in immunology · 2026Review
- Real-World Identification of Eosinophilic COPD Patients Potentially Eligible for Dupilumab: A Retrospective Observational Study.International journal of chronic obstructive pulmonary disease · 2026Observational
- The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies.Frontiers in immunology · 2026Review
- Development of a phased discharge planning for patients undergoing airway stenting: a Delphi study informed by the timing it right framework.Frontiers in medicine · 2026Article
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.Frontiers in immunology · 2026Review
- Dual role of IL-17A in COPD: amplifier of inflammatory cascades and mediator of airway remodeling and alveolar destruction.Frontiers in immunology · 2026Review
- Established and Emerging Biological Therapies for the Treatment of Comorbid Asthma and Chronic Obstructive Pulmonary Disease.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with limited response to standard anti-inflammatory therapies. Biologics targeting specific inflammatory pathways have emerged as potential treatments, but their efficacy remains variable across distinct COPD endotypes. Objective: To systematically evaluate the efficacy and trial quality of biologics tested in COPD patients using a multicriteria decision analysis (MCDA) approach, with attention to type 2 (T2) and non-T2 inflammatory targets. Methods: We assessed 20 trials encompassing 12 biologics and 9294 patients with COPD. Each trial was scored (0-3 per domain, total 12 points) across four domains: exacerbation reduction, lung function improvement, biomarker stratification, and trial design quality. Results: Dupilumab (anti-IL-4Rα) demonstrated the most robust efficacy in eosinophilic COPD, with consistent reductions in exacerbation rates and improvements in FEV Conclusion: Biologics targeting T2 inflammation offer therapeutic promise in eosinophilic COPD when guided by biomarkers. Conversely, current biologics directed at non-T2 and alarmin pathways yield limited or inconsistent benefits, emphasizing the need for improved phenotyping and targeted intervention strategies in non-eosinophilic COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.